Ono Pharmaceutical Co., Ltd.

TSE:4528 Stock Report

Market Cap: JP¥820.8b

Ono Pharmaceutical Valuation

Is 4528 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 4528 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 4528 (¥1747.5) is trading below our estimate of fair value (¥5118.81)

Significantly Below Fair Value: 4528 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4528?

Key metric: As 4528 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 4528. This is calculated by dividing 4528's market cap by their current earnings.
What is 4528's PE Ratio?
PE Ratio8.6x
EarningsJP¥95.13b
Market CapJP¥820.81b

Price to Earnings Ratio vs Peers

How does 4528's PE Ratio compare to its peers?

The above table shows the PE ratio for 4528 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average20.3x
4151 Kyowa Kirin
15.4x6.1%JP¥1.3t
4536 Santen Pharmaceutical
22.1x11.5%JP¥578.6b
4523 Eisai
32x13.1%JP¥1.3t
4507 Shionogi
11.5x-0.3%JP¥1.8t
4528 Ono Pharmaceutical
8.6x-5.8%JP¥820.8b

Price-To-Earnings vs Peers: 4528 is good value based on its Price-To-Earnings Ratio (8.6x) compared to the peer average (20.3x).

Price to Earnings Ratio vs Industry

How does 4528's PE Ratio compare vs other companies in the JP Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
4528 8.6xIndustry Avg. 15.0xNo. of Companies5PE01020304050+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 4528 is good value based on its Price-To-Earnings Ratio (8.6x) compared to the JP Pharmaceuticals industry average (15x).

Price to Earnings Ratio vs Fair Ratio

What is 4528's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4528 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio8.6x
Fair PE Ratio18.2x

Price-To-Earnings vs Fair Ratio: 4528 is good value based on its Price-To-Earnings Ratio (8.6x) compared to the estimated Fair Price-To-Earnings Ratio (18.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 4528 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentJP¥1,747.50
JP¥2,116.92
+21.1%
32.2%JP¥4,370.00JP¥1,700.00n/a13
Nov ’25JP¥1,958.00
JP¥2,151.54
+9.9%
31.0%JP¥4,370.00JP¥1,800.00n/a13
Oct ’25JP¥1,932.00
JP¥2,182.94
+13.0%
30.5%JP¥4,370.00JP¥1,800.00n/a13
Sep ’25JP¥2,156.00
JP¥2,221.40
+3.0%
29.5%JP¥4,370.00JP¥1,800.00n/a13
Aug ’25JP¥2,154.50
JP¥2,306.01
+7.0%
27.6%JP¥4,370.00JP¥1,800.00n/a13
Jul ’25JP¥2,221.00
JP¥2,505.83
+12.8%
26.8%JP¥4,370.00JP¥1,900.00n/a12
Jun ’25JP¥2,275.00
JP¥2,597.50
+14.2%
32.9%JP¥5,170.00JP¥1,900.00n/a12
May ’25JP¥2,324.00
JP¥2,714.17
+16.8%
29.3%JP¥5,170.00JP¥2,000.00n/a12
Apr ’25JP¥2,468.50
JP¥2,672.50
+8.3%
30.8%JP¥5,170.00JP¥1,800.00n/a12
Mar ’25JP¥2,487.50
JP¥2,689.17
+8.1%
30.7%JP¥5,170.00JP¥1,800.00n/a12
Feb ’25JP¥2,525.50
JP¥2,720.77
+7.7%
28.5%JP¥5,170.00JP¥2,000.00n/a13
Jan ’25JP¥2,516.00
JP¥2,747.69
+9.2%
27.6%JP¥5,170.00JP¥2,100.00n/a13
Dec ’24JP¥2,708.00
JP¥2,755.38
+1.7%
27.4%JP¥5,170.00JP¥2,100.00n/a13
Nov ’24JP¥2,561.00
JP¥2,733.08
+6.7%
24.5%JP¥4,780.00JP¥2,100.00JP¥1,958.0013
Oct ’24JP¥2,868.00
JP¥2,870.91
+0.1%
26.4%JP¥4,780.00JP¥2,100.00JP¥1,932.0011
Sep ’24JP¥2,768.50
JP¥2,844.62
+2.7%
24.7%JP¥4,780.00JP¥2,100.00JP¥2,156.0013
Aug ’24JP¥2,705.00
JP¥2,829.23
+4.6%
25.1%JP¥4,780.00JP¥2,100.00JP¥2,154.5013
Jul ’24JP¥2,606.00
JP¥2,881.67
+10.6%
24.7%JP¥4,780.00JP¥2,200.00JP¥2,221.0012
Jun ’24JP¥2,620.50
JP¥3,038.46
+15.9%
22.6%JP¥4,700.00JP¥2,200.00JP¥2,275.0013
May ’24JP¥2,753.00
JP¥3,184.62
+15.7%
19.9%JP¥4,700.00JP¥2,500.00JP¥2,324.0013
Apr ’24JP¥2,764.00
JP¥3,215.38
+16.3%
18.9%JP¥4,700.00JP¥2,500.00JP¥2,468.5013
Mar ’24JP¥2,782.50
JP¥3,276.92
+17.8%
18.3%JP¥4,700.00JP¥2,500.00JP¥2,487.5013
Feb ’24JP¥2,863.00
JP¥3,308.33
+15.6%
13.7%JP¥4,100.00JP¥2,700.00JP¥2,525.5012
Jan ’24JP¥3,083.00
JP¥3,810.00
+23.6%
15.0%JP¥4,530.00JP¥2,700.00JP¥2,516.0013
Dec ’23JP¥3,498.00
JP¥3,794.62
+8.5%
15.0%JP¥4,530.00JP¥2,700.00JP¥2,708.0013
Nov ’23JP¥3,369.00
JP¥3,779.23
+12.2%
15.1%JP¥4,530.00JP¥2,700.00JP¥2,561.0013

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Shionogi

JP¥1.8t

Engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan.

4507

JP¥2,094.50

7D

-2.1%

1Y

-10.9%

Tsumura

JP¥368.9b

Manufactures and sells pharmaceutical products from crude drugs derived from plants and other natural products in Japan and internationally.

4540

JP¥4,858.00

7D

1.2%

1Y

76.3%

Daito PharmaceuticalLtd

JP¥32.8b

Manufactures and sells pharmaceutical products worldwide.

4577

JP¥2,147.00

7D

1.8%

1Y

8.8%